First Head-to-Head Study In Branch Retinal Vein Occlusion(BRVO) Announced In Europe And Israel

Allergan Ltd. announced today the first head-to-head study in branch retinal vein occlusion (BRVO), a sight threatening eye condition that impacts approximately 300,000 people in the EU each year1,2...

Full Story →